Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00328107 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults
A Phase 2 study, sponsored by Protein Sciences Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 459
- Enrollment target
NCT00328107 is a Phase 2 study that has completed, run by Protein Sciences Corporation. The registered enrollment target is 459 participants.
The verdict
NCT00328107, a Phase 2 study, has completed, sponsored by Protein Sciences Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 459 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the dose-related safety, immunogenicity, and protective efficacy of a trivalent recombinant hemagglutinin influenza vaccine in healthy adults.
Interventions
- BIOLOGICAL Influenza Vaccine, recombinant Hemagglutinin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 459 participants |
| Start Date | 2004-11 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00328107
The ClinicalTrials.gov registry entry for NCT00328107 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 459 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Protein Sciences Corporation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Influenza Vaccine, recombinant Hemagglutinin is the first listed.
NCT00328107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00328107 about?
NCT00328107 is a clinical study titled "Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults". The purpose of this study was to determine the dose-related safety, immunogenicity, and protective efficacy of a trivalent recombinant hemagglutinin influenza vaccine in healthy adults.
What is the current status of trial NCT00328107?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 459 participants. The study started on 2004-11. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00328107?
The interventions under investigation include: Influenza Vaccine, recombinant Hemagglutinin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00328107?
This trial is sponsored by Protein Sciences Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.